Cardio-Oncology Fellow
University of Toronto
University of Toronto
Aeugst am Albis, Zurich, Switzerland
RODRIGO CARRASCO
I am Rodrigo Carrasco, MD, PhD, and I have just completed my second year of the Cardio-Oncology Fellowship at the University of Toronto under the supervision of Dr. Dinesh Thavendiranthan, Dr. Husam Abdel-Qadir and Dr. Diego Delgado, at the Peter Munk Cardiac Center and the Ted Rogers Center for Heart Research, University Health Network, Ontario, Toronto.
During my Fellowship, in addition to evaluating patients with potentially cardiotoxic cancer therapies, I had the opportunity to regularly monitor patients with ATTR Cardiac Amyloidosis, who were receiving Tafamidis therapy, but also new therapies such as AG10 or Vutrisiran as part of Clinical Trials. My Fellowship also included research projects. The topic of one of the research projects was related to the study of cardiotoxicity of new cancer immunotherapies such as CAR-T, BiTEs and TILs. The second research project was related to the clinical and echocardiographic evaluation of the effect of treatments such as Tafamidis for patients with ATTR Cardiac amyloidosis, in order to detect early which patient could benefit the most, and whose preliminary results are presented at this congress.
Previously to my Cardio-oncology Fellowship, I have done clinical rotations in cardio-oncology units in Spain and Italy, as well as a rotation in Cardiac Imaging at the University of Zurich.
I did my specialty in Internal Medicine and Cardiology at the University of Chile, in addition to a PhD in Medical Sciences also at the University of Chile. In Chile, I was part of the Cardio-Oncology advisory team of the Ministry of Health of the Government of Chile, which carried out the first Chilean clinical guidelines in Cardio-Oncology.
Regarding my previous research work, I participated as a principal and co-investigator in Pilot Clinical Trials in Chile to prevent anthracyclines cardiotoxicity with intervention based on carvedilol plus DHA (ISRCTN69560410).
Saturday, October 29, 2022
5:15 PM – 5:30 PM EDT